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Abstract
Background: Two phylogenetic lineages of influenza B virus coexist and circulate in the human population
(B/Yamagata and B/Victoria) but only one B-strain is included in each seasonal vaccine. Mismatch regularly occurs
between the recommended and circulating B-strain. Inclusion of both lineages in vaccines may offer better
protection against influenza.
Methods: This study (NCT00714285) assessed the immunogenicity and safety of two candidate quadrivalent
influenza vaccines (QIV) containing two A- and two B-strains (one from each lineage) in adults (18–60 years).
Subjects were randomized and stratified by age to receive either QIV (non-adjuvanted or low-dose adjuvanted
[LD QIV-AS]) or trivalent influenza vaccine (TIV, non-adjuvanted or low-dose adjuvanted [LD TIV-AS]), N = 105 in all
treatment groups. The study evaluated the statistical non-inferiority of the immunological response elicited by QIV
and LD QIV-AS versus TIV and LD TIV-AS and the statistical superiority of the response elicited by the quadrivalent
vaccines against the B-strain (B/Jiangsu) not included in the TIV.
Results: Pre-defined non-inferiority and superiority criteria were reached for both QIVs compared to the TIVs. On
Day 21 in all vaccine groups SCRs were ≥54.8%, SPRs ≥88.5% and SCFs ≥5.4 for the A strains and B strain included
in all vaccines (B/Malaysia). This fulfilled the European (CHMP) and the US (CBER) licensing criteria for the
assessment of influenza vaccines in adults (CHMP criteria: SCR > 40%, SPR > 70%, SCF > 2; CBER criteria: LL of 95% CI
for SPR ≥ 70% or SCR ≥ 40%). Only the QIVs met the CHMP and CBER criteria for the B/Jiangsu strain. In the QIV and
LD-QIV-AS groups, the SCFs were 9.1 and 8.1, respectively and the SPRs were 98.1% and 95.2%, whereas for the TIV
and LD-TIV-AS groups, the SCFs were 2.3 and 2.5, respectively, and the SPRs were 75.0% and 63.8%, with the LLs of
the 95% CI <70% for SPR and <40% for SCR.
Conclusions: Addition of a fourth strain did not impact the immune response elicited by the three original strains
contained in the TIV. A clear immunological benefit was seen with the QIV formulation for the second B-strain,
indicating that quadrivalent vaccines could provide broader protection against influenza.
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Background
Seasonal influenza affects 5 to 15% of the worldwide
population in all age groups every year, and causes high
morbidity and mortality, as well as substantial socio-
economic disruption [1]. Currently, the influenza viruses
in circulation in the human population are A(H1N1), A
(H3N2) and two distinct lineages of B-strain: the B/
Victoria/2/87 and B/Yamagata/16/88 lineages [2]. These
have coexisted since 1983 in the human population [3],
and both strains have circulated broadly worldwide since
1988 [1,2,4,5].
The B influenza strain is the major cause of an epidemic
every 2 to 4 years, with infection occurring in all age
groups [6]. Influenza B causes a substantial number of
hospitalizations and deaths and, although seasonal mortal-
ity estimates are highest for the H3N2 strain, the impact
of B-strains is greater than that of H1N1 [7,8]. From 1976
to 1999, 16% of the influenza-associated deaths in the US
were caused by influenza B and occurred mostly in the
elderly population, although they also represent 46% of all
influenza related death in children below the age of 5
years [8].
Current seasonal influenza vaccines include the two A-
strains (H1N1 and H3N2) but only one B-strain [9]. The
prediction for which B-strain to include in the vaccine is
not always accurate [6], giving rise to a variable level of
mismatch between the B-strain contained in the vaccine
and the B-strain causing infection and disease each sea-
son. In 6 of the past 11 years, in the US, the main circulat-
ing B-virus did not match the strain recommended and
included in the vaccine [10]. In the EU, mismatch oc-
curred in 4 out of 8 seasons between the 2003/2004 and
2010/2011 Northern Hemisphere influenza seasons [11].
During seasons with a mismatch of B-strains, protection is
reduced in adults and even more so in children [12-15]
because cross-reactivity between the two B-strain lineages
is limited [2,16,17]. In vaccine-naïve children, live attenu-
ated influenza vaccines have a high vaccine efficacy against
well-matched B-viruses, but provide only poor or no
cross-protection against strains of the opposite B-lineage
[13]. In order to ensure increased vaccine coverage against
viruses of both B-lineages, one option may be to include
one strain of each lineage in the influenza vaccine, and in
doing so potentially offer a better protection against influ-
enza disease [16,18]. In recognition of the value of a
quadrivalent influenza vaccine, the World Health Or-
ganization for the first time in February 2012 issued a rec-
ommendation for a strain of the alternate B lineage to be
included in quadrivalent influenza vaccines made for the
2012–2013 Northern Hemisphere immunization cam-
paigns [19].
Adjuvanted vaccines have been shown to be highly im-
munogenic and well tolerated in children and adults, pro-
viding an important antigen-sparing strategy [20,21] and
cross immunogenicity between clades of the same lineage
[21]. Thus, the use of adjuvants may be a way to address
possible concerns regarding the manufacturing capability
to handle a fourth strain within the short timeframe of
seasonal production.
This study was the first conducted by GlaxoSmithKline
Vaccines to assess, in adults aged 18 to 60 years, the
immunogenicity and safety of an influenza vaccine
containing four strains (two A-strains: H1N1 and H3N2
and two B-strains: Victoria and Yamagata lineages), with
and without adjuvant, and using 2 different doses of
hemagglutinin (15 μg and 5 μg hemagglutinin in the




The study was approved by the study center ethics com-
mittee and conducted in accordance with Good Clinical
Practice (GCP) and all applicable regulatory requirements
including the Declaration of Helsinki. Written informed
consent was obtained from all participants prior to study
entry. This was a Phase I/II, single-center, single-blind,
controlled study conducted in the Czech Republic (re-
gistered at www.ClinicalTrials.gov: NCT00714285). The
study ran from July 2008 until January 2009, with approxi-
mately 6 months duration per subject. Participants were
randomized on a 1:1:1:1 basis to four parallel treatment
groups using an internet-based system that employed a
minimization procedure accounting for center and age.
Each participant received one intramuscular injection, into
the deltoid region of the non-dominant arm, of their
assigned vaccine: quadrivalent influenza vaccine (QIV),
low-dose adjuvanted QIV (LD QIV-AS), trivalent influ-
enza vaccine (TIV), or low-dose adjuvanted TIV (LD TIV-
AS). The participants were unaware of the treatment
assigned during the course of the trial. Blood samples
were collected prior to immunization (Day 0) and 21 days
post-vaccination (Day 21). Vaccine administration during
study was recorded in an electronic case report form. A
summary of the protocol is available at www.gsk-
clinicalstudyregister.com (ID 111295).
Study population
Participants were healthy adults aged 18 to 60 years who
the investigator believed would comply with the study re-
quirements. Women of childbearing age were required to
use reliable contraception. Exclusion criteria included:
pregnant or lactating women, confirmed influenza infec-
tion during the previous year, influenza vaccination during
the 2007–2008 season, a history of hypersensitivity to an
influenza vaccine or any component of the vaccine, any
immunosuppressive or immunodeficient condition.
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Vaccines
The vaccines used were all inactive split-virion vaccines
manufactured by GlaxoSmithKline (GSK) Vaccines. All
vaccines contained the A/Solomon Islands/03/2006
[H1N1] IVR-145 strain, A/Wisconsin/67/2005 [H3N2]
NYMCX strain and B/Malaysia/2506/2004 strain (Victoria
lineage), according to recommendations for the 2007–
2008 season [22]. The QIV vaccines included an additional
strain: the B/Jiangsu/10/2003 strain (Yamagata lineage).
The QIV and TIV vaccines contained 15 μg hemagglutinin
(HA) of each strain, whereas the adjuvanted formulations
(LD QIV-AS and LD TIV-AS) contained 5 μg HA of each
strain. Both adjuvanted vaccines contained 62.5 μL of
AS03, an α-tocopherol, oil-in-water emulsion-based Adju-
vant System (squalene 10.69 mg, tocopherol 5.8 mg). All
vaccines were supplied in pre-filled syringes containing a
0.5 mL dose.
Study objectives
The first primary objective was to evaluate, in terms
of hemagglutination inhibition (HI) , the statistical non-
inferiority of the immunological response elicited by the
quadrivalent vaccines compared to the trivalent vaccines
(QIV vs. TIV and LD QIV-AS vs. LD TIV-AS) for the
three recommended seasonal strains. A co-primary object-
ive aimed at assessing the statistical superiority of the im-
munological response elicited by the quadrivalent vaccines
compared to the trivalent vaccines (QIV vs. TIV and LD
QIV-AS vs. LD TIV-AS) for the B/Jiangsu strain, not in-
cluded in the TIV formulations. Secondary objectives were
to evaluate the statistical non-inferiority of the immuno-
logical response measured by HI and elicited by LD QIV-
AS vs. QIV, and to assess the safety and reactogenicity of
the four study vaccines in terms of solicited local and gen-
eral adverse events (AEs) 7 days post-vaccination, unsoli-
cited AEs during the 21 days post-vaccination and serious
adverse events (SAEs) and occurrence of potential
immune-mediated diseases (pIMD) during the 6-month
study period.
Immunogenicity evaluation
All serum samples were analyzed in the GlaxoSmithKline
Vaccines laboratories: HI assay was performed in
GlaxoSmithKline laboratory located in Laval, Canada and
neutralization assay in Dresden, Germany. HI was as-
sessed by a validated HI micro-titer assay using chicken
erythrocytes against the four vaccine strains [23]. Geomet-
ric mean titers (GMTs), seroconversion rates (SCRs),
seroprotection rates (SPRs) and seroconversion factors
(SCFs) were calculated with their 95% confidence intervals
(CI). SCR was defined as the percentage of subjects with
either a pre-vaccination HI titer <10 and a post-vac-
cination titer ≥40 or a pre-vaccination titer ≥10 and a
minimum four-fold increase in post-vaccination titer. SPR
was defined as the percentage of subjects with a serum HI
titer ≥40. SCF was defined as the fold increase in serum
HI GMT per strain on Day 21 compared to Day 0. Assess-
ment of the HI response was based on the CHMP and the
US Food and Drug Administration (FDA) Center for Bio-
logics Evaluation and Research (CBER) guidance targets
for seasonal influenza vaccines [24,25]. The CHMP criteria
for subjects aged 18 to 60 years are that the point estimate
of SPR is >70%, or SCR is >40% or SCF is >2. The CBER
criteria for subjects aged 18 to 64 years are that the lower
limit of the 95% CI for SPR is ≥70% or for SCR is ≥40%.
Microneutralizing (MN) antibody titers against both B-
strains were also assessed according to previously de-
scribed methods [26,27]. The 50% neutralization titers
were calculated using the Reed and Muench method [28].
The cut-off was a MN titer of 1:28 with participants con-
sidered to be seronegative if no neutralizing activity was
present at a base dilution of 1:28. Seronegative samples
were assigned a titer of 14 for calculations. As no protect-
ive neutralizing correlate is established, GMT and SCR
(defined as ≥4-fold increase in titer relative to the baseline
value) were used to characterize the immune response.
Reactogenicity and safety evaluation
All participants were provided with diary cards to record
solicited and unsolicited AEs. Local (pain, redness and
swelling at the injection site) and systemic (arthralgia, fa-
tigue, headache, myalgia, nausea, shivering and fever)
AEs were recorded on the day of vaccination and for the
six subsequent days.
Statistical analysis
The target sample size was 100 participants per group
with the assumption that approximately 5% of participants
would not be evaluable for immunogenicity endpoints.
Thus, 420 subjects were planned to be enrolled into this
study with 105 per group. This sample size was not driven
by a power calculation, but assuming a standard deviation
of 0.5 for the individual HI titers, a precision of 16% was
expected on the GMT ratio estimates of interest. Demo-
graphic characteristics were tabulated as a whole and per
vaccine group. The analysis of the HI response was based
on the per-protocol cohort for immunogenicity. GMTs,
SCRs, SCFs and SPRs were all estimated with their 95%
CIs.
Non-inferiority and superiority objectives were assessed
for each vaccine strain by estimating GMT ratios (QIV /
TIV) 21 days after vaccination. GMTs were estimated
using an Analysis of Covariance (ANCOVA) model in-
cluding treatment as the fixed effect and baseline as covar-
iate was fitted on log10 transformed post-vaccination HI
titer for each strain. Adjusted GMT ratios were obtained
from these models with their 95% CIs. In terms of GMT
ratio, non-inferiority and superiority were demonstrated if
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the lower bound of the 95% CIs of the ratio estimates were
higher than 0.67 and 1, respectively. The MN response was
analyzed in a subset of participants belonging to the per-
protocol cohort for immunogenicity. Both GMTs and
SCRs were estimated for each group for only the B-strains.
The analysis of safety was performed on the total vacci-
nated cohort (TVC). Incidence rates of AEs with 95% CIs
were calculated for each group.
Results
Study population
In July 2008, 420 participants (105 in each treatment
group) were enrolled and vaccinated. Overall, 416 sub-
jects completed the study: 105 in the QIV group, 104 in
the TIV group, 102 in the LD QIV-AS group and 105 in
the LD TIV-AS group (Figure 1). All but one participant
were of White-Caucasian/European heritage. The mean
age was 37.6 years and 60.0% were female (Table 1).
Immunogenicity
HI response
All four study vaccines exceeded both the CHMP criteria
set for the yearly evaluation of seasonal influenza vaccines
in participants aged 18 to 60 years [25] and the CBER cri-
teria for the licensure of influenza vaccines in adults aged
18 to 64 years [24] for the three recommended seasonal
strains (A/Solomon Islands, A/Wisconsin and B/Malaysia
420 participants enrolled, 
randomized and vaccinated (TVC)
105 completed study 
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Figure 1 Participant flow diagram. Abbreviations: N = number of participants; LD QIV-AS = low-dose of quadrivalent influenza vaccine
adjuvanted with AS03; LD TIV-AS = low-dose of trivalent influenza vaccine adjuvanted with AS03; QIV = quadrivalent influenza vaccine;
TIV = trivalent influenza vaccine; TVC = total vaccinated cohort No participants were withdrawn due to SAEs.








Nb 104 104 104 105 417
Age (years)










Median 38.0 37.0 33.5 36.0 36.0
Range
(min–max)
19–59 18–59 18–59 18–59 18–59
Gender n(%)
Female 60 (57.7) 66 (63.5) 66 (63.5) 58 (55.2) 250 (60.0)




1 (1.0) 0 0 0 1 (0.2)
White
Caucasian
103 (99.0) 104 (100) 104 (100) 105 (100) 416 (99.8)
a Groups were administered the quadrivalent influenza vaccine (QIV), the
low-dose adjuvanted quadrivalent influenza vaccine (LD QIV-AS), the low-dose
adjuvanted trivalent influenza vaccine (LD TIV-AS) or the trivalent influenza
vaccine (TIV).
b Abbreviations: N = total number of participants, n(%) = number (percentage)
of participants with characteristic, min–max =minimum to maximum,
SD = standard deviation.
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strains). Only the QIV and LD QIV-AS vaccines met all
the CHMP and the CBER criteria for the B/Jiangsu strain
(Table 2). QIV and LD QIV-AS were shown to be non-
inferior to TIV and LD TIV-AS for the three strains
contained in the TIV; the lower limits of the 95% CI of
GMT ratios for HI antibodies to the three recommended
seasonal strains were above the pre-defined limit of 0.67
(Figure 2). Superiority of the response elicited by both
QIV and LD QIV-AS as compared to TIV and LD TIV-AS
was also shown for the B/Jiangsu strain. Lower limits of
the 95% CI of GMT ratios for HI antibodies to the B/
Jiangsu strain were above the pre-defined limit of 1
(Figure 2), with responses 3 to 4 times higher with the
QIV formulations compared to the TIV vaccines. Further-
more, the immunogenicity of LD QIV-AS was shown to
be non-inferior to that of QIV with the adjusted GMT ra-
tios (LD QIV-AS/QIV) being 1.15 (95% CI 0.85–1.55) for
A/Solomon Islands, 1.21 (0.97–1.52) for A/Wisconsin,
Table 2 Summary of immunogenicity for the per-protocol cohort
Treatment groupa
Vaccine Strain QIV LD QIV-AS LD TIV-AS TIV
Nb 104 104 104 105
A/Solomon Islands
GMT (95% CI) Pre 21.4 (16.1–28.4) 22.2 (16.6–29.5) 23.3 (17.5–31.0) 18.4 (14.3–23.7)
Post 130.0 (106.1–159.4) 150.6 (118.4–191.5) 160.4 (129.1–199.3) 133.8 (105.6–169.7)
SCR %(95% CI) Post 56.7 (46.7–66.4)*$ 57.7 (47.6–67.3)* $ 54.8 (44.7–64.6)* $ 60.0 (50.0–69.4)* $
SPR %(95% CI) Pre 37.5 (28.2–47.5) 42.3 (32.7–52.4) 40.4 (30.9–50.5) 35.2 (26.2–45.2)
Post 92.3 (85.4–96.6)* $ 88.5 (80.7–93.9)* $ 93.3 (86.6–97.3)* $ 90.5 (83.2–95.3)* $
SCF (95% CI) Post 6.1 (4.6–8.0)* 6.8 (5.0–9.2)* 6.9 (5.0–9.4)* 7.3 (5.3–9.9)*
A/Wisconsin
GMT (95% CI) Pre 29.3 (23.0–37.3) 25.7 (19.8–33.3) 30.7 (23.7–39.8) 29.0 (22.5–37.4)
Post 162.1 (138.0–190.4) 189.5 (158.9–226.0) 197.9 (169.1–231.7) 156.3 (127.5–191.6)
SCR %(95% CI) Post 60.6 (50.5–70.0)* $ 66.3 (56.4–75.3)* $ 64.4 (54.4–73.6)* $ 59.0 (49.0–68.5)* $
SPR %(95% CI) Pre 51.0 (41.0–60.9) 46.2 (36.3–56.2) 53.8 (43.8–63.7) 55.2 (45.2–65.0)
Post 97.1 (91.8–99.4)* $ 98.1 (93.2–99.8)* $ 100 (96.5–100)* $ 96.2 (90.5–99.0)* $
SCF (95% CI) Post 5.5 (4.4–6.9)* 7.4 (5.8–9.4)* 6.4 (5.0–8.3)* 5.4 (4.1–7.0)*
B/Malaysia
GMT (95% CI) Pre 32.2 (24.8–41.8) 26.6 (20.2–35.0) 23.2 (17.7–30.4) 27.2 (20.6–35.8)
Post 192.8 (159.6–232.9) 213.0 (174.0–260.9) 187.0 (151.9–230.3) 188.5 (150.0–237.0)
SCR %(95% CI) Post 57.7 (47.6–67.3)* $ 65.4 (55.4–74.4)* $ 56.7 (46.7–66.4)* $ 59.0 (49.0–68.5)* $
SPR %(95% CI) Pre 51.0 (41.0–60.9) 47.1 (37.2–57.2) 42.3 (32.7–52.4) 44.8 (35.0–54.8)
Post 97.1 (91.8–99.4)* $ 97.1 (91.8–99.4)* $ 96.2 (90.4–98.9)* $ 93.3 (86.7–97.3)* $
SCF (95% CI) Post 6.0 (4.7–7.7)* 8.0 (6.1–10.5)* 8.1 (5.9–11.0)* 6.9 (5.2–9.3)*
B/Jiangsu
GMT (95% CI) Pre 19.6 (15.6–24.8) 19.5 (15.4–24.5) 23.4 (18.3–29.7) 19.2 (15.2–24.3)
Post 179.1 (151.4–211.9) 158.3 (130.7–191.9) 59.2 (47.3–74.0) 43.4 (34.5–54.6)
SCR %(95% CI) Post 76.0 (66.6–83.8)* $ 78.8 (69.7–86.2)* $ 26.9 (18.7–36.5) 19.0 (12.0–27.9)
SPR %(95% CI) Pre 31.7 (22.9–41.6) 38.5 (29.1–48.5) 43.3 (33.6–53.3) 39.0 (29.7–49.1)
Post 98.1 (93.2–99.8)* $ 95.2 (89.1–98.4)* $ 75.0 (65.6–83.0)* 63.8 (53.9–73.0)
SCF (95% CI) Post 9.1 (7.2–11.5)* 8.1 (6.6–10.0)* 2.5 (2.1–3.0)* 2.3 (1.9–2.6)
a Groups were administered the quadrivalent influenza vaccine (QIV), the low-dose adjuvanted quadrivalent influenza vaccine (LD QIV-AS), the low-dose
adjuvanted trivalent influenza vaccine (LD TIV-AS) or the trivalent influenza vaccine (TIV).
b Abbreviations: 95% CI = 95% confidence interval (lower limit–upper limit); GMT = geometric mean titer; N = total number of participants; Pre = Pre-vaccination
(Day 0); Post = Post-vaccination (Day 21); SCR = Seroconversion ratio defined as percentage of participants with antibody titer ≥1:40 1/DIL post-vaccination for
initially seronegative participants, or ≥4 fold the pre-vaccination antibody titer for initially seropositive participants; SPR = Seroprotection rate defined as
percentage of participants with antibody titer ≥1:40; SCF = Seroconversion factor defined as the fold increase in GMTs post-vaccination compared
with pre-vaccination.
* CHMP criteria were met or exceeded (SCR > 40%, SPR > 70%, SCF > 2.5).
$ CBER criteria were met or exceeded (95% CI lower limit for SCR ≥ 40%, SPR ≥ 70%).
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1.16 (0.88–1.53) for B/Malaysia and 0.89 (0.71–1.11) for
B/Jiangsu.
MN response
On Day 21, the GMTs (95% CI) for the neutralizing anti-
bodies to B/Malaysia strain were: 226.1 [165.7–308.6] in
QIV group, 316.1 [226.3–441.6] in LD QIV-AS group,
296.9 [206.2–427.4] in LD TIV-AS group and 255.8
[183.8–355.9] in TIV group, with the CIs overlapping
between the trivalent and the quadrivalent formulations.
For the B/Jiangsu strain the highest CIs were observed
for the quadrivalent vaccines (QIV: 157.0 [115.5–213.4],
LD QIV-AS: 161.1 [120.9–214.7], LD TIV-AS 65.6
[47.9–89.9] and TIV: 38.4 [29.3–50.3]). Similar observa-
tions were made for SCR on Day 21 (Figure 3).
Safety
The majority of participants (range: 67.6%–86.5%) re-
ported at least one symptom (solicited or unsolicited) dur-
ing the 7-day post-vaccination period (Table 3). Local
symptoms were reported more often than general symp-
toms for all vaccine groups. Grade 3 symptoms (solicited
and unsolicited) were reported by 3.8% (TIV), 3.8% (QIV),
9.5% (LD TIV-AS) and 4.8% (LD QIV-AS) of participants.
Pain at the injection site was the most frequently reported
solicited local symptom for all vaccine groups (range:
49.5%–76.0%, Table 3). Grade 3 pain occurrence was low

























Figure 2 Adjusted GMT ratios on Day 21 (ATP cohort for immunogenicity). Adjusted GMT ratios for A/Solomon Islands, A/Wisconsin, B/
Malaysia and B/Jiangsu (only included in QIV formulations) on Day 21 for all treatment groups in the per-protocol cohort for immunogenicity.
The margin for superiority of response was if the 95% CI lower limit was ≥1 and the margin for non-inferiority of response was if the 95% CI
lower limit was ≥0.67. The data points represent the adjusted GMT ratio for QIV group over the TIV group (QIV/TIV; diamond) or the LD QIV-AS
group over the LD TIV-AS group (LD QIV-AS/LD TIV-AS; square) with their associated 95% confidence intervals (CIs). Abbreviations: LD QIV-AS:
low-dose adjuvanted quadrivalent influenza vaccine; LD TIV-AS: low-dose adjuvanted trivalent influenza vaccine; QIV: quadrivalent influenza
vaccine; TIV: trivalent influenza vaccine.
Figure 3 Summary of results of microneutralizing antibody
assay for B influenza strains. Note: Seroconversion rates (SCRs) of
the microneutralizing antibody assay in all treatment groups.
Neutralizing antibody responses to B/Malaysia and B/Jiangsu
were measured before vaccination (Day 0, Pre) and 21 days
post-vaccination (Day 21, Post). SCRs, defined as ≥4-fold increase in
titer relative to the value noted at baseline, are presented with the
associated 95% CI. Abbreviations: LD QIV-AS: low-dose adjuvanted
quadrivalent influenza vaccine; LD TIV-AS: low-dose adjuvanted
trivalent influenza vaccine; QIV: quadrivalent influenza vaccine; TIV:
trivalent influenza vaccine.
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AS: 2.9%), and absent with the unadjuvanted vaccines.
The incidence of other solicited local symptoms (redness
and swelling at the injection site) was low (≤ 6.7%, Table 3).
Fatigue (range: 30.5%–45.2%), myalgia (14.3%–38.5%) and
headache (21.9%–31.7%) were the most frequently
reported solicited general symptoms considered to be re-
lated to vaccination for all vaccine groups. Grade 3 general
reactogenicity was low (≤ 7.6%, Table 3). One SAE was
reported in the TIV Group (prolonged hospitalization for
hemorrhage after tonsillectomy), which was not consid-
ered to be related to vaccination. No fatal SAEs occurred
and no pIMD were reported up to day 180 after
vaccination.
Discussion
Trivalent influenza vaccines recommended for im-
munization against influenza contain the two A-strains
(H1N1 and H3N2) but only one B-strain selected each
year in the Yamagata-like lineage group or the Victoria-
like one [9,29]. The efficacy and effectiveness of influenza
vaccines depend on the degree of similarity between the
circulating viruses and those included in the vaccine [12].
The present study was conducted to examine how the
addition of another strain would affect the immune re-
sponse and reactogenicity observed with a TIV. The
addition of a fourth strain in the QIV vaccine formulations
did not impact the immune response elicited in healthy
Table 3 Safety and reactogenicity on Days 0–6 post-vaccination (TVC)
Treatment groupa
Symptom % (95% CI)b QIV LD QIV-AS LD TIV-AS TIV
Nc 105 104 105 105
Any symptom 79.0 (70.0–86.4) 86.5 (78.4–92.4) 77.1 (67.9–84.8) 67.6 (57.8–76.4)
Grade 3d 3.8 (1.0–9.5) 4.8 (1.6–10.9) 9.5 (4.7–16.8) 1.9 (0.2–6.7)
Local Symptoms 72.4 (62.8–80.7) 76.9 (67.6–84.6) 70.5 (60.8–79.0) 49.5 (39.6–59.5)
Grade 3 0 (0–3.5) 1.9 (0.2–6.8) 2.9 (0.6–8.1) 0 (0–3.5)
Pain 72.4 (62.8–80.7) 76.0 (66.6–83.8) 70.5 (60.8–79.0) 49.5 (39.6–59.5)
Grade 3 0 (0–3.5) 1.9 (0.2–6.8) 2.9 (0.6–8.1) 0 (0–3.5)
Redness 2.9 (0.6–8.1) 5.8 (2.1–12.1) 4.8 (1.6–10.8) 1.0 (0–5.2)
>100 mm 0 (0–3.5) 0 (0–3.5) 0 (0–3.5) 0 (0–3.5)
Swelling 2.9 (0.6–8.1) 3.8 (1.1–9.6) 6.7 (2.7–13.3) 1.9 (0.2–6.7)
>100 mm 0 (0–3.5) 0 (0–3.5) 0 (0–3.5) 0 (0–3.5)
General Symptoms 44.8 (35.0–54.8) 57.7 (47.6–67.3) 53.3 (43.3–63.1) 43.8 (34.1–53.8)
Grade 3 3.8 (1.0–9.5) 4.8 (1.6–10.9) 7.6 (3.3–14.5) 1.9 (0.2–6.7)
Arthalgia 5.7 (2.1–12.0) 24.0 (16.2–33.4) 12.4 (6.8–20.2) 10.5 (5.3–18.0)
Grade 3 1.0 (0–5.2) 2.9 (0.6–8.2) 1.9 (0.2–6.7) 0 (0–3.5)
Fatigue 30.5 (21.9–40.2) 45.2 (35.4–55.3) 34.3 (25.3–44.2) 31.4 (22.7–41.2)
Grade 3 1.9 (0.2–6.7) 3.8 (1.1–9.6) 2.9 (0.6–8.1) 1.0 (0–5.2)
Headache 22.9 (15.2–32.1) 31.7 (22.9–41.6) 24.8 (16.9–34.1) 21.9 (14.4–31.0)
Grade 3 2.9 (0.6–8.1) 1.9 (0.2–6.8) 1.0 (0–5.2) 0 (0–3.5)
Myalgia 16.2 (9.7–24.7) 38.5 (29.1–48.5) 31.4 (22.7–41.2) 14.3 (8.2–22.5)
Grade 3 1.0 (0–5.2) 2.9 (0.6–8.2) 2.9 (0.6–8.1) 1.0 (0–5.2)
Nausea 7.6 (3.3–14.5) 9.6 (4.7–17.0) 7.6 (3.3–14.5) 7.6 (3.3–14.5)
Grade 3 1.9 (0.2–6.7) 1.9 (0.2–6.8) 1.9 (0.2–6.7) 1.0 (0–5.2)
Shivering 3.8 (1.0–9.5) 9.6 (4.7–17.0) 8.6 (4.0–15.6) 3.8 (1.0–9.5)
Grade 3 1.0 (0–5.2) 1.9 (0.2–6.8) 1.0 (0–5.2) 0 (0–3.5)
Fever (°C) 1.0 (0–5.2) 2.9 (0.6–8.2) 1.9 (0.2–6.7) 1.0 (0–5.2)
>39°C 0 (0–3.5) 0 (0–3.5) 0 (0–3.5) 0 (0–3.5)
a Groups were administered the quadrivalent influenza vaccine (QIV), the low-dose adjuvanted quadrivalent influenza vaccine (LD QIV-AS), the low-dose
adjuvanted trivalent influenza vaccine (LD TIV-AS) or the trivalent influenza vaccine (TIV).
b Abbreviations: 95% CI = 95% confidence interval (lower limit–upper limit).
c N = total number of participants with symptom sheets returned.
d Grade 3 symptoms were defined as symptoms that prevented normal everyday activity.
Table displays local and general symptoms reported as related to vaccination. All reported local symptoms were considered related to vaccination.
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adults aged 18 to 60 years to the three strains contained in
the TIV vaccines, as demonstrated by the statistical non-
inferiority of the immunological response elicited by QIV
and LD QIV-AS over TIV and LD TIV-AS 21 days after
vaccination. Furthermore, the response elicited against the
B/Jiangsu strain contained in the QIV formulations, but
not in the trivalent vaccines was shown to be superior in
terms of levels of antibodies reached 21 days after vaccin-
ation. As shown in other studies [30], some levels of cross
reactive antibodies were elicited in this adult population
against the heterologuous B strains by the TIV formu-
lations. However, levels of antibodies indicative of
seroprotection were only reached with the QIV formula-
tions in the present study. The criteria as defined in the
CHMP and CBER guidelines for seasonal influenza vac-
cines in adults were met for the A/Solomon Islands, A/
Wisconsin and B/Malaysia strains for all four vaccine
groups. Nevertheless, only the quadrivalent formulations
were able to elicit the level of immunological response re-
quired to fulfill all CHMP and CBER criteria against the
B/Jiangsu strain 21 days after vaccination. The micro-
neutralization assay results confirmed the data obtained
with HI assay. Similar results were previously reported
with a quadrivalent live attenuated vaccine containing two
influenza subtype A strains (A/H1N1 and A/H3N2) and
two B strains (B/Yamagata and B/Victoria). This live atten-
uated vaccine was shown to be non-inferior to trivalent
live attenuated vaccines both in adults and in children
[31,32].
As a clinical impact on vaccine efficacy has been sug-
gested or described in several studies when the circulating
strain belonged to the other B lineage [13,14,30,33-35],
the immunological improvement elicited by QIV formula-
tions is likely to translate into a direct clinical benefit.
Additionally, the use of quadrivalent vaccines including an
influenza B strain representing both lineages could result
in substantial cost-savings. Recently, two modeling papers
[36,37] evaluated the potential benefits associated with the
use of a quadrivalent vaccine compared with a TIV for the
time period 1999–2009 in the US. Based on the clinical
burden of influenza illness and viral surveillance data, the
Center for Disease Control and Prevention estimated that
the use of a QIV rather than a TIV between 1999 and
2009 could have resulted in additional reductions in the
number of cases of influenza illnesses, influenza-associ-
ated respiratory hospitalizations, and influenza-related re-
spiratory deaths [36]. Furthermore, Lee et al. calculated
that the use of QIV during the same time period may have
been associated with substantial cost-savings for society
and third party payers (median savings: $3.1 billion and
$292 million, respectively) [37].
Another objective of the present study was to see
whether an adjuvant would trigger cross reactive anti-
bodies against the 2 B lineages. GlaxoSmithKline Vaccines
proprietary α-tocopherol, oil-in-water emulsion-based Ad-
juvant System, AS03, has been shown to elicit cross-
reactive response against drifted influenza strains [21]. In
the present study adjuvant alone was not sufficient to in-
duce a cross-reactive immune response to the B/Jiangsu
strain, which may be expected as the two B-strains are
genetically too distinct [3] and so may not be simply con-
sidered as drift variants. However, a dose-sparing effect
has been demonstrated with the use of 5 μg HA per strain
in the adjuvanted formulations (20 μg HA/dose) instead
of 15 μg in the non-adjuvanted vaccines (60 μg HA/dose),
as illustrated by the immunological non-inferiority of LD
QIV-AS vs. QIV. This is in line with other studies using
AS03 adjuvant [21,38].
In terms of reactogenicity, no clinically relevant impact
was found with the addition of a fourth strain in the
vaccines. The safety profile of the study vaccines was
comparable to that seen in other studies conducted in
adults [39-41]. The non adjuvanted QIV formulation
reactogenicity profile was generally similar to the TIV vac-
cine. As expected, the adjuvanted vaccines had a higher
reactogenicity profile compared to the non-adjuvanted
formulations, being associated with a higher incidence of
solicited injection site and general symptoms. Similar ob-
servations were reported in previous clinical trials of influ-
enza A/H1N1pdm09 [38,42-44] and H5N1 [45] vaccines
comparing safety outcomes between adjuvanted and non-
adjuvanted vaccines. Local and general adverse events
tended to be more frequent with adjuvanted vaccines
compared with non-adjuvanted vaccines, in both adults
and children. No potentially related serious adverse events
were reported during the conduct of the study. However,
our study with 105 vaccines per vaccine group was not
designed to assess rare events.
Another limitation of the current study is the absence
of further follow-up of the participants. Additional infor-
mation (beyond 21 days post vaccination) on the im-
mune responses to the additional B-strain, including
data on the persistence of antibodies against B/Jiangsu
strain during the influenza season, would be of interest.
Another limitation is that the study enrolled relatively
young participants (<60 years of age). Whether our find-
ings can be extended to other populations such as the
elderly, with decreased immune response to influenza
vaccines [46] remains to be evaluated.
Conclusions
As observed by others [1,2], this study confirms that
adults vaccinated against one B-lineage type have reduced
post-vaccination GMTs and a lower percentage of titers ≥
40 to viruses from the alternative lineage. Consequently,
adults vaccinated with influenza vaccine against one type
B-lineage would have reduced protection against infection
with the heterologuous lineage if it were circulating.
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The use of a quadrivalent influenza vaccine, containing
B-strains from both circulating lineages, could therefore
provide a broader protection against influenza infection,
while maintaining a similar safety profile.
This study, conducted at a single site in Czech Republic,
provides evidence of the benefit of QIV vaccination to the
participants of this study aged between 18 and 60 years.
Other clinical studies have been conducted to confirm this
finding in a broader adult population, as well as in other
populations, including children and elderly persons (re-
gistered at www.ClinicalTrials.gov: NCT01204671 and
NCT01196988).
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